ERBB2 and breast carcinoma: Regarding breast cancer, some areas are already been consolidated: real-life studies have suggested us that mCHT is an effective treatment especially in HR+/HER2-ve advanced breast cancer patients without visceral crisis and with limited tumor burden, and elderly patients [132].